AJOVista’s Oric Pharmaceuticals ORIC Stock Holding History

AJOVista’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-4,357	Closed	-$40.1K	–	311
2023 Q4	$40.1K	Buy	+4,357	New	+$31.5K	0.05%	316

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AJOVista's ORIC Position: Q1 2024 in Review

AJOVista sold out of Oric Pharmaceuticals (ORIC) in Q1 2024, closing a stake of 4,357 shares — an estimated $40.1K sold.

AJOVista first reported a position in ORIC in Q4 2023 and held it in 1 quarter. The position peaked at $40.1K in Q4 2023. 112 funds tracked by Wall St. Rank hold ORIC as of Q1 2024.

AJOVista reported no remaining Oric Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
AJOVista sold 4,357 Oric Pharmaceuticals shares in Q1 2024, an estimated $40.1K.
AJOVista first reported a position in Oric Pharmaceuticals in Q4 2023 and held it in 1 quarter.
AJOVista's Oric Pharmaceuticals position peaked at $40.1K in Q4 2023.
112 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2024.

Based on AJOVista's 13F filing for Q1 2024, filed 10 May 2024.